Managing @entity2299 in XXXX : suggested guidelines for a population characterized by low levels of high density lipoprotein @entity165 .

@entity1 @entity101 @entity233 @entity2299 @entity301 @entity412 @entity165
Based on data from the Turkish Society of Cardiology and others, it is established that Turks have a high prevalence of @entity301 ( @entity301 ). Several risk factors are prominent in Turks: @entity2299 , cigarette smoking, and @entity101 . The @entity2299 is unique in that very low levels of HDL-C and typically "normal" LDL-C levels characterize the Turkish population. The low HDL-C levels appear to be genetic in origin and are largely independent of high @entity412 levels (73% of Turkish @entity1 and 94% of @entity1 with HDL-C <40 mg/dl have @entity412 levels <150 mg/dl; only 15% of @entity1 and 3% of @entity1 with HDL-C <40 mg/dl have @entity412 levels >200 mg/dl). HDL-C levels are 10-15% mg/dl lower in Turks than seen in the United States or western Europe. Low HDL-C is a major risk factor; @entity301 risk increases 2-4% for every 1 mg/dl decrease in HDL-C levels. Existing treatment guidelines focus on plasma LDL-C levels and fail to take into account the continuous increase in @entity301 risk that occurs as HDL-C levels decrease. However, several studies show that @entity1 with @entity301 or free of @entity301 but with multiple risk factors, who have low HDL-C and near optimal LDL-C, benefit very significantly from lipid-lowering therapy. Many of these @entity1 with low HDL-C levels do not qualify for drug therapy based on existing guidelines. Therefore, we believe that unique guidelines must be developed to guide the treatment of low HDL-C Turkish @entity1 . We suggest that treatment based on both the LDL-C level and the total @entity165 /HDL-C (TC/HDL-C) ratio is the best way to address treatment of @entity1 with low HDL-C levels. The most effective drug treatment available presently in @entity233 relies on lowering LDL-C levels to optimize the TC/HDL-C ratio.
